<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>130(9)</volume><submitter>Mendis S</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Pancreatic cancer incidence is increasing in younger populations. Differences between early onset pancreatic cancer (EOPC) and later onset pancreatic cancer (LOPC), and how these should inform management warrant exploration in the contemporary setting.&lt;h4>Methods&lt;/h4>A prospectively collected multi-site dataset on consecutive pancreatic adenocarcinoma patients was interrogated. Patient, tumour, treatment, and outcome data were extracted for EOPC (≤50 years old) vs LOPC (>50 years old).&lt;h4&gt;Results&lt;/h4>Of 1683 patients diagnosed between 2016 and 2022, 112 (6.7%) were EOPC. EOPC more frequently had the tail of pancreas tumours, earlier stage disease, surgical resection, and trended towards increased receipt of chemotherapy in the curative setting compared to LOPC. EOPC more</pubmed_abstract><journal>British journal of cancer</journal><pagination>1477-1484</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11058801</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data.</pubmed_title><pmcid>PMC11058801</pmcid><pubmed_authors>Knowles B</pubmed_authors><pubmed_authors>To YH</pubmed_authors><pubmed_authors>Wong R</pubmed_authors><pubmed_authors>Zielinski R</pubmed_authors><pubmed_authors>McLachlan SA</pubmed_authors><pubmed_authors>Thomson B</pubmed_authors><pubmed_authors>Chee CE</pubmed_authors><pubmed_authors>Michael M</pubmed_authors><pubmed_authors>Usatoff V</pubmed_authors><pubmed_authors>Shapiro J</pubmed_authors><pubmed_authors>Lee B</pubmed_authors><pubmed_authors>Lipton L</pubmed_authors><pubmed_authors>Clarke K</pubmed_authors><pubmed_authors>Nikfarjam M</pubmed_authors><pubmed_authors>Ananda S</pubmed_authors><pubmed_authors>Loveday B</pubmed_authors><pubmed_authors>Gibbs P</pubmed_authors><pubmed_authors>Mendis S</pubmed_authors><pubmed_authors>Fox A</pubmed_authors><pubmed_authors>Pattison S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data.</name><description>&lt;h4>Background&lt;/h4>Pancreatic cancer incidence is increasing in younger populations. Differences between early onset pancreatic cancer (EOPC) and later onset pancreatic cancer (LOPC), and how these should inform management warrant exploration in the contemporary setting.&lt;h4>Methods&lt;/h4>A prospectively collected multi-site dataset on consecutive pancreatic adenocarcinoma patients was interrogated. Patient, tumour, treatment, and outcome data were extracted for EOPC (≤50 years old) vs LOPC (>50 years old).&lt;h4&gt;Results&lt;/h4>Of 1683 patients diagnosed between 2016 and 2022, 112 (6.7%) were EOPC. EOPC more frequently had the tail of pancreas tumours, earlier stage disease, surgical resection, and trended towards increased receipt of chemotherapy in the curative setting compared to LOPC. EOPC more</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2025-04-18T13:30:32.979Z</modification><creation>2025-04-06T23:18:24.729Z</creation></dates><accession>S-EPMC11058801</accession><cross_references><pubmed>38448752</pubmed><doi>10.1038/s41416-024-02619-5</doi></cross_references></HashMap>